Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tetrodotoxin - WEX Pharmaceuticals

Drug Profile

Tetrodotoxin - WEX Pharmaceuticals

Alternative Names: 9401-TTX; Halneuron; Tectin; Tetrodin; Tocudin

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Medical University; WEX Pharmaceuticals
  • Class Anaesthetics; Analgesics; Antiarrhythmics; Drug withdrawal therapies; Quinazolines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cancer pain
  • Phase II Neuropathic pain; Pain; Peripheral nervous system diseases
  • Suspended Opioid-related disorders
  • No development reported Anaesthesia

Most Recent Events

  • 01 Mar 2024 WEX Pharmaceuticals completes a phase II trial in Pain (In volunteers, In adults) in Netherlands (SC) (ISRCTN78737401)
  • 26 Apr 2022 Discontinued - Phase-II for Cancer pain in China (Parenteral)
  • 19 Apr 2022 Phase-II clinical trials in Neuropathic pain (In adults, In the elderly) in Singapore (SC) (NCT05359133)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top